[Enzymes as starting points for pharmaceutical development].
作者信息
Wagner G
出版信息
Pharmazie. 1984 Mar;39(3):190-4.
PMID:6728894
Abstract
摘要
相似文献
1
[Enzymes as starting points for pharmaceutical development].[以酶作为药物研发的起点]
Pharmazie. 1984 Mar;39(3):190-4.
2
Thymidylate synthase inhibitors.
Cancer Chemother Biol Response Modif. 2001;19:1-19.
3
Sequence-based identification of specific drug target regions in the thymidylate synthase enzyme family.基于序列的胸苷酸合成酶酶家族中特定药物靶标区域的鉴定。
ChemMedChem. 2008 Mar;3(3):392-401. doi: 10.1002/cmdc.200700215.
4
Prodrugs of thymidylate synthase inhibitors: potential for antibody directed enzyme prodrug therapy (ADEPT).胸苷酸合成酶抑制剂的前药：抗体导向酶前药疗法（ADEPT）的潜力。
Anticancer Drug Des. 1996 Dec;11(8):625-36.
5
Future challenges in the clinical development of thymidylate synthase inhibitor compounds.
Oncol Res. 1997;9(8):403-10.
6
Thymidyl biosynthesis enzymes as antibiotic targets.胸苷生物合成酶作为抗生素靶点。
Appl Microbiol Biotechnol. 2007 Feb;74(2):282-9. doi: 10.1007/s00253-006-0763-1. Epub 2007 Jan 11.
7
[The biochemical basis of pharmaceutical chemistry. 10. Enzymes and enzyme inhibitors as drugs].[药物化学的生化基础。10. 作为药物的酶和酶抑制剂]
Pharmazie. 1991 May;46(5):365-82.
8
Thymidylate synthase inhibitors.胸苷酸合成酶抑制剂
Cancer Chemother Biol Response Modif. 2005;22:1-18.
9
Thymidylate synthase inhibitors as anticancer agents: from bench to bedside.胸苷酸合成酶抑制剂作为抗癌药物：从实验室到临床应用
Cancer Chemother Pharmacol. 2003 Jul;52 Suppl 1:S80-9. doi: 10.1007/s00280-003-0625-9. Epub 2003 Jun 18.
10
[Critical remarks on trimethoprim/sulfonamide combinations in veterinary medicine].[关于兽医学中三甲氧苄氨嘧啶/磺胺类药物组合的批判性评论]
Dtsch Tierarztl Wochenschr. 1984 Apr 9;91(4):135-9.
Zotero 插件